EHC

Key Points to Consider Before Investing in EHC Stock

Shares of Encompass Health have moved 1.2% today, and are now trading at a price of $71.45. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 737,709 compared to the stock's average volume of 560,138.

Encompass Health Corporation provides post-acute healthcare services in the United States. Based in Birmingham, United States the company has 36,900 full time employees and a market cap of $7,161,862,144. Encompass Health currently offers its equity investors a dividend that yields 0.9% per year.

The company is now trading -8.92% away from its average analyst target price of $78.45 per share. The 11 analysts following the stock have set target prices ranging from $70.0 to $85.0, and on average give Encompass Health a rating of buy.

Over the last 52 weeks, EHC stock has risen 36.0%, which amounts to a 26.0% difference compared to the S&P 500. The stock's 52 week high is $71.96 whereas its 52 week low is $45.11 per share. With its net margins declining an average -5.5% over the last 4 years, Encompass Health may not have a strong enough profitability trend to support its stock price.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023-02-27 4,348,600 271,000 6.23 -39.34
2022-02-25 4,014,900 412,200 10.27 28.86
2021-02-26 3,566,300 284,200 7.97 1.92
2020-02-27 4,605,000 359,900 7.82 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS